NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

ADAs to Alemtuzumab

NCT06310343

CompletedN/A

Sponsor: Queen Mary University of London

Conditions: Multiple Sclerosis

Interventions: Alemtuzumab

Countries: United Kingdom

The main aim is to quantify the changes in alemtuzumab antibody-anti-alemtuzumab over a 24 months period

Eligibility overview

Sex: ALL

Age: 18 Years to 55 Years

Healthy volunteers: Yes

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

1. Patients with RRMS who are being treated with alemtuzumab at Barts Health NHS Trust will be approached to participate in the study.
2. Patients must be willing and able to undergo blood tests.

Exclusion Criteria:

1. Ineligible for alemtuzumab under NHS England prescribing guidelines.
2. Those unable to comply with study requirements, including frequency of visits. Abnormal baseline investigations (WBC\<3 x 10\*9/l, lymphocytes \<1.0 x 10\*9/l, neutrophil count \<1.5 x 10\*9/l, platelet count \<100 x 10\*9/l, haemoglobin \<110 g/l, LFT \>/3x upper limit of normal of site reference ranges, potassium \<2.8 mmol/l or \>5.5 mmol/l, sodium /,125 mmol/l, creatinine \>130 umol/l).

Locations (1)

London, Second Floor Neurophys Dept, United Kingdom